• Study reports abnormally high VTE and high bleed risk in critically ill COVID-19 patients and calls for more effective prevention strategies.
  • Clinicians at NHS hospitals are supporting the care of COVID-19 patients with the use of geko™ devices to reduce the risk of blood clots in the most at risk patients.
Learn more Contact us

Community Care geko™ device roll-out in Canada


Firstkind Ltd, a Sky Medical Technology company, is delighted to report that Erie St. Clair Community Care Access Centre (CCAC) has announced geko™ device roll-out in Canada, in treating wound care patients where other treatments have previously been unsuccessful.

The roll-out is the result of an Erie St. Clair CCAC trial where the geko™ device had been used to treat chronic wound patients, leading to the healing of wounds that had previously lasted from months to years.

At the Erie St. Clair CCAC we look at products that are time and cost-effective” said Lucy Coppola, Director, Transitional and Short Stay Services. “The geko™ is a unique, highly effective device. The application is an easily teachable skill for patients comfortable with managing their own care”. 

Wounds generally heal using oxygenated blood from the heart. For some people, however, the blood doesn’t circulate properly causing swelling and oedema. The geko™ device is applied to the lower leg and helps stimulate blood flow using a small electrical impulse.

Lynn Allen, with a wound caused by cellulitis that hadn’t healed after nearly four months, tried the geko™ device. “Within a week or two I could see it working”, said Allen, who after six months of using the device, no longer needs it. “Not only did this method reduce my wound to nothing more than a mark, it also helped improve circulation in my leg overall”.

The geko™ is wireless, weighs only 10 grams, takes less than 60 seconds to fit, and doesn’t restrict patient mobility.

The Erie St. Clair CCAC’s geko™ trial began in May 2014 in partnership with Perfuse Medtec and the Hamilton Niagara Haldimand Brant CCAC. The trial focused on patients who had tried other forms of wound healing without success and quickly resulted in home visits reduced from daily to as little as two visits per week. Some patients experienced complete healing and were discharged from services altogether. The ESC CCAC has now fully rolled-out the geko™ program.

The geko™, a neuromuscular electrostimulation device, stimulates the common peroneal nerve activating the calf and foot muscle pumps, increasing venous, arterial and microcirculatory blood flow, up to 60% to that of walking. Originally created for the prevention of venous thromboembolism (VTE), the device can also treat patients with lower-limb wounds.